Institutional investors purchased a net $1.8 million shares of RGEN during the quarter ended December 2017. This may signal that the smart money is gaining interest in this company as the 87.57% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
SUMMIT CREEK ADVISORS LLC Bought 88.8 Thousand shares of Repligen Corp
JENNISON ASSOCIATES LLC Bought 24.2 Thousand shares of Repligen Corp